Novel anti-human pai-1 antibody
US-2016369008-A1 · Dec 22, 2016 · US
Thrombin/plasmin-regulated antibodies that bind TFPI
US9975962B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9975962-B2 |
| Application number | US-201314389219-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 14, 2013 |
| Priority date | Mar 30, 2012 |
| Publication date | May 22, 2018 |
| Grant date | May 22, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This disclosure provides protease-regulated antibodies which specifically bind to tissue factor pathway inhibitor (TFPI). The antibodies are useful for treating bleeding disorders such as hemophilia.
First claim
Opening claim text (preview).
The invention claimed is: 1. A protease-regulated antibody which specifically binds to tissue factor pathway inhibitor (TFPI), comprising: (a) the amino acid sequence of SEQ ID NO: 131 which comprises the variable light domain and constant light domain of the protease-regulated antibody and the protease cleavage site of SEQ ID NO: 137; and (b) the amino acid sequence of SEQ ID NO: 133 which comprises the variable heavy domain and constant heavy domain of the protease-regulated antibody and the protease cleavage site of SEQ ID NO: 137, wherein the protease-regulated antibody binds TFPI and promotes the generation of thrombin or plasmin.
Assignees
Inventors
Classifications
Fab or Fab' · CPC title
comprising antibodies · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
- C07K16/38Primary
against protease inhibitors of peptide structure · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9975962B2 cover?
- This disclosure provides protease-regulated antibodies which specifically bind to tissue factor pathway inhibitor (TFPI). The antibodies are useful for treating bleeding disorders such as hemophilia.
- Who is the assignee on this patent?
- Bayer Healthcare Llc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/38. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 22 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).